Lugano Doreen, Mwangi Kennedy, Mware Bernard, Kibet Gilbert, Osiany Shebbar, Kiritu Edward, Dobi Paul, Muli Collins, Njeru Regina, de Oliveira Tulio, Njenga M Kariuki, Routh Andrew, Oyola Samuel O
International Livestock Research Institute, Nairobi, Kenya.
Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, Texas, USA.
J Virol. 2025 Jun 17;99(6):e0048225. doi: 10.1128/jvi.00482-25. Epub 2025 May 6.
Vaccination is a key control measure of coronavirus disease 2019 by preventing severe effects of disease outcomes, reducing hospitalization rates and death, and increasing immunity. However, vaccination can affect the evolution and adaptation of SARS-CoV-2 largely through vaccine-induced immune pressure. Here, we investigated intrahost recombination and single nucleotide variations (iSNVs) on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome in non-vaccinated and vaccinated sequences from the Kenyan population to profile intrahost viral genetic evolution and adaptations driven by vaccine-induced immune pressure. We identified recombination hotspots in the S, N, and ORF1a/b genes and showed the genetic evolution landscape of SARS-CoV-2 by comparing within- and inter-wave recombination events from the beginning of the pandemic (June 2020 to December 2022) in Kenya. We further reveal differential expression of recombinant RNA species between vaccinated and non-vaccinated individuals and perform an in-depth analysis of iSNVs to identify and characterize the functional properties of non-synonymous mutations found in ORF-1 a/b, S, and N genes. Lastly, we detected a minority variant in non-vaccinated patients in Kenya, with an immune escape mutation S255F of the spike gene, and showed differential recombinant RNA species. Overall, this work identified unique mutations and intrahost recombination patterns in SARS-CoV-2, which could have significant implications for virus evolution, virulence, and immune escape.IMPORTANCEThe impact of vaccination on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genetic diversity in Kenya and much of Africa remains unknown. This can be attributed to lower sequencing rates; however, this information is relevant to improvement in vaccine and antiviral research. In this study, we investigated how vaccination and SARS-CoV-2 transmission waves affect intrahost non-homologous recombination and single nucleotide variations (iSNVs). We identified unique mutations and intrahost recombination patterns in SARS-CoV-2, which could have significant implications for virus evolution, virulence, and immune escape. We also demonstrate a methodology for studying genetic changes in a pathogen by a simultaneous analysis of both intrahost single nucleotide variations and recombination events. The study reveals the diversity of SARS-CoV-2 in Kenya and highlights the need for sustained genomic surveillance in Kenya and Africa to better understand how the virus evolves. Such surveillance ensures detection of drifts in evolution, allowing information for updates in vaccines, policy making, and containment of future variants of SARS-CoV-2.
接种疫苗是控制2019冠状病毒病的一项关键措施,可预防疾病严重后果、降低住院率和死亡率,并增强免疫力。然而,接种疫苗在很大程度上可通过疫苗诱导的免疫压力影响严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的进化和适应性。在此,我们研究了肯尼亚人群中未接种疫苗和接种疫苗序列的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)基因组上的宿主内重组和单核苷酸变异(iSNV),以描绘由疫苗诱导的免疫压力驱动的宿主内病毒基因进化和适应性。我们在S、N和ORF1a/b基因中鉴定出重组热点,并通过比较肯尼亚疫情开始(2020年6月至2022年12月)期间不同波次的宿主内和宿主间重组事件,展示了SARS-CoV-2的基因进化图景。我们进一步揭示了接种疫苗和未接种疫苗个体之间重组RNA种类的差异表达,并对iSNV进行了深入分析,以鉴定和表征在ORF-1a/b、S和N基因中发现的非同义突变的功能特性。最后,我们在肯尼亚未接种疫苗的患者中检测到一种少数变异株,其刺突基因存在免疫逃逸突变S255F,并展示了不同的重组RNA种类。总体而言,这项工作在SARS-CoV-2中鉴定出独特的突变和宿主内重组模式,这可能对病毒进化、毒力和免疫逃逸具有重要意义。
重要性 接种疫苗对肯尼亚及非洲大部分地区的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)基因多样性的影响尚不清楚。这可能归因于测序率较低;然而,这些信息与改进疫苗和抗病毒研究相关。在本研究中,我们调查了接种疫苗和SARS-CoV-2传播波如何影响宿主内非同源重组和单核苷酸变异(iSNV)。我们在SARS-CoV-2中鉴定出独特的突变和宿主内重组模式,这可能对病毒进化、毒力和免疫逃逸具有重要意义。我们还展示了一种通过同时分析宿主内单核苷酸变异和重组事件来研究病原体基因变化的方法。该研究揭示了肯尼亚SARS-CoV-2的多样性,并强调了在肯尼亚和非洲持续进行基因组监测的必要性,以更好地了解病毒如何进化。这种监测可确保检测到进化中的变异,为更新疫苗、制定政策和控制SARS-CoV-2未来变异株提供信息。
J Virol. 2025-6-17
Front Immunol. 2025-6-4
Cochrane Database Syst Rev. 2025-6-20
Nucleic Acids Res. 2024-1-5
Commun Med (Lond). 2023-6-19
Signal Transduct Target Ther. 2023-5-23
Biochemistry (Mosc). 2022-12